(Amherst, NH) – Transdermal drug developers are being challenged by a market that is growing in range as well as depth. The availability of APIs in patch and gel form for indications beyond hormone replacement are creating opportunities to penetrate therapeutic segments that represent sustainable growth models. Over the coming decade, growth in demand for prescription drug patches will be driven by several factors – factors with strong demographic and population trend underpinnings.
Neurology – Patients with diseases of the central nervous system are often faced with challenges that include compromised cognition and diminished dexterity that make it difficult to adhere to drug protocols based on oral formulations. Drug patches present the opportunity to mitigate these impediments.
Pain Management – Pain is now viewed as an important and treatable element of modern patient care. Several factors are now converging to create opportunities for pain management products that address the overlapping needs of caregivers, underwriters, and patients.
Contraception – Contraception represents a very large market opportunity for transdermal patch suppliers. Clinic and supply methods of contraception account for approximately 83 percent of contraceptive practice world-wide. These methods, the ones most frequently offered by family planning programs, account for a larger fraction of contraceptive use in developing than in developed countries – about 90 percent and 65 percent, respectively.
Other Growth Segments – With the aging of the population worldwide, conditions and diseases such as menopause, osteoporosis and heart disease, which require long-term therapy, are expected to become significantly more prevalent.
More than forty companies have transdermal drug products under development for either initial approval or expanded indications. These products and candidates comprise thirty separate APIs and target more than twenty distinct therapeutic indications.
More information is available at www.greystoneassociates.org .
About Greystone
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.
Contact:
Mark Smith
Voice: 603-595-4340
Fax: 603-804-0466
www.greystoneassociates.org
Source: Greystone Associates
